Antibodies

31 May 2010

Prolia(R) (Denosumab) Granted Marketing Authorization in the European Union

27 May 2010

Progenics Presents Novel Monoclonal Antibodies against Clostridium difficile at the American Society for Microbiology Conference

25 May 2010

Biogen Idec and Abbott Announce Enrollment of First Patient in Global Phase III Study of Daclizumab for Relapsing-Remitting Multiple Sclerosis

24 May 2010

NANOBODY LEAD CANDIDATE SELECTED BY BOEHRINGER INGELHEIM FOR DEVELOPMENT IN ALZHEIMER’S DISEASE

24 May 2010

Controlled Phase 2 Study of Ipilimumab Shows Clinical Activity in Advanced Non-Small Cell Lung Cancer

24 May 2010

Seattle Genetics and Millennium Complete Enrollment of Brentuximab Vedotin (SGN-35) Phase II ALCL Trial

22 May 2010

Ranibizumab significantly more effective than standard of care in treating vision loss due to DME, a serious complication of diabetes

21 May 2010

Ligand Pharmaceuticals Inc. (LGND) Acquired Milestone and Royalty Interest in AstraZeneca PLC (AZN) IL-9 Program for Asthma For $2.75 Million

20 May 2010

Phase III Study Showed First-Line Maintenance Use of Rituxan Improved the Likelihood of People with Follicular Lymphoma Living without Their Disease Worsening

20 May 2010

ABLYNX ANNOUNCES A THIRD EXTENSION OF ITS ANTI-TNF-ALPHA NANOBODY COLLABORATION WITH PFIZER

19 May 2010

Roche and Biogen Idec announce their decision to discontinue the ocrelizumab clinical development programme in patients with rheumatoid arthritis

19 May 2010

ImaginAb, Inc. and GlaxoSmithKline Establish Collaboration

18 May 2010

REDECTANE meets both endpoints specificity and sensitivity with superiority over CT in its pivotal Phase III trial

17 May 2010

BioInvent and ThromboGenics to Receive €10 Million Milestone as Partner Roche Begins New Clinical Study with TB-403

17 May 2010

FibroGen Reports Preclinical Data Showing that FG-3019 Reversed the Process of Fibrosis in the Lung

17 May 2010

Anti-Pseudomonas Activity of KaloBios’/sanofi pasteur’s KB001 May Prevent Serious Lung Infections and Limit Damaging Inflammation

17 May 2010

Hawthorn Pharmaceuticals and the University of Pittsburgh Sign Exclusive Global Licensing Agreement of CSPG4 Specific Monoclonal Antibodies

17 May 2010

Emergent BioSolutions IND for Anthrax Monoclonal Antibody Therapeutic Clears FDA Review

14 May 2010

Amgen Submits Denosumab Biologics License Application to FDA for the Reduction of Skeletal Related Events in Cancer Patients

13 May 2010

Regeneron Provides Initial Data on Two Antibody Product Candidates

13 May 2010

Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders

6 May 2010

Boehringer Ingelheim and Micromet Announce Global Collaboration for Multiple Myeloma BiTE Antibody

6 May 2010

BioInvent and ThromboGenics Announce Positive Topline Results from Phase II VTE Prophylaxis Study with Anti-Factor VIII (TB-402)

3 May 2010

Bristol-Myers Squibb Receives Complete Response Letter from FDA for Belatacept

2 May 2010

New Efficacy Data Shows Cimzia(R) (certolizumab pegol) Provides Long-Term Remission of Moderate to Severe Crohn’s Disease Regardless of Prior Anti-TNF Exposure, According to Data Presented at DDW

27 April 2010

BioSante Pharmaceuticals Enters Option Agreement to its 2A/Furin Antibody Expression Technology

26 April 2010

RoACTEMRA recommended for approval in Europe for the reduction of joint damage and improvement in physical function in rheumatoid arthritis

26 April 2010

Symphogen Announces Publication in Molecular Biotechnology of Sympress II Production System Allowing Single-Batch Recombinant Polyclonal Antibody Manufacturing

26 April 2010

TRACON Announces Start of Phase 1/2 Trial of TRC105 Antibody Therapy for Prostate Cancer

22 April 2010

Biotie to continue development of and maintain global rights to BTT-1023, its novel VAP-1 antibody for inflammatory disease

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

B7-H4 Targeted Antibody Therapy Pipeline Review

TL1A Inhibitor Pipeline Review

TROP-2-Targeted Immunotherapy Pipeline Review

2023 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

CCR8-Targeted Antibody Immunotherapy Pipeline Review

Eculizumab (Soliris) Biosimilars & Biosuperiors Pipeline Review

CD73 Inhibitor Pipeline Review

Mesothelin-Targeted Immunotherapy Pipeline Review

RNA-Targeted Small Molecules 2019: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

IGF-1R- and IGF-1 Targeted Immunotherapy Pipeline Review